Evidence map›Paper›PMID 33770116›Full record

ArticlePloS one2021

GM-1111 reduces radiation-induced oral mucositis in mice by targeting pattern recognition receptor-mediated inflammatory signaling.

Abigail Pulsipher, Justin R Savage, Thomas P Kennedy, Kavita Gupta, Benjamin G Cuiffo, Stephen T Sonis, Won Yong Lee

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. The Role of the Innate Immune Response in Oral Mucositis Pathogenesis.International journal of molecular sciences · 2023
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Abigail PulsipherGlycoMira Therapeutics, Salt Lake City, Utah, United States of America.
Justin R SavageGlycoMira Therapeutics, Salt Lake City, Utah, United States of America.
Thomas P KennedyGlycoMira Therapeutics, Salt Lake City, Utah, United States of America.
Kavita GuptaGlycoMira Therapeutics, Salt Lake City, Utah, United States of America.
Benjamin G CuiffoBiomodels, Waltham, Massachusetts, United States of America.
Stephen T SonisBiomodels, Waltham, Massachusetts, United States of America.
Won Yong LeeGlycoMira Therapeutics, Salt Lake City, Utah, United States of America.ORCID 0000-0001-7915-1829
GlycoMira Therapeutics (United States) · US

Funding

A Novel Glycosaminoglycan-Based Therapeutic for Chronic RhinosinusitisR44AI126987 · NIAID · GLYCOMIRA, LLC · PI SAVAGE, JUSTIN RODNEY · 2018 to 2022
$4.4M
Glycosaminoglycans to Treat and Prevent Radiation-Induced Oral MucositisSB1DE024024 · NIDCR · GLYCOMIRA, LLC · PI SAVAGE, JUSTIN RODNEY · 2021 to 2023
$2.8M
Glycosaminoglycans to Treat and Prevent Radiation-Induced Oral MucositisR44DE024024 · NIDCR · GLYCOMIRA, LLC · PI LEE, WON YONG · 2016 to 2017
$746k
Glycosaminoglycans to Treat and Prevent Radiation-Induced Oral MucositisR43DE024024 · NIDCR · GLYCOMIRA, LLC · PI LEE, WON YONG · 2014 to 2014
$200k
NIAID NIH HHS R44 AI126987NIDCR NIH HHS R43 DE024024NIDCR NIH HHS R44 DE024024NIDCR NIH HHS SB1 DE024024
6 · The paper itself

Abstract

purposeOral mucositis (OM) is a common, painful side effect of radiation therapy used for the treatment of head and neck cancer (HNC). Activation of the innate immune system upon irradiation has been identified as a key precipitating event of OM. To better understand OM's pathogenesis, we studied pattern recognition receptors (PRRs) and their downstream pro-inflammatory cytokines in a mouse model of radiation-induced OM. We also tested therapeutic efficacy of GM-1111 that targets innate immune system to reduce radiation-induced OM. METHODS AND MATERIALS: The pathogenesis of OM was studied in a single X-ray induced mouse model. The severity of OM was measured by visual and microscopical examinations. The irradiation-induced changes of PRRs and their downstream effector cytokine gene expression levels were determined. The efficacy of GM-1111 to reduce OM was tested in single and fractionated irradiation mouse models. The impact of the drug on tumor response to radiation therapy was also tested in a mouse model of human HNC.

resultsRadiation-induced tissue ulcerations were radiation-dosage and -time dependent. The lesions showed selective increases in PRR and pro-inflammatory cytokine gene expression levels. Once daily administration of GM-1111 (≥30 mg/kg, s.c.) significantly reduced the severity and the incidence of OM. The drug had little effect on PRRs but significantly inhibited downstream pro-inflammatory cytokine genes. GM-1111 did not interfere radiation therapy to induce HNC SCC-25 tumor regression. Instead, we observed significant drug-induced tumor regression.

conclusionsRadiation induces tissue damages. The increased expression levels of PRRs and their downstream pro-inflammatory cytokine genes in the damaged tissues suggest their important contribution to the pathogenesis of OM. Drug GM-1111 that targets these innate immune molecules may be a potential drug candidate as an intervention for OM.

Indexed as

Receptors, Pattern RecognitionSignal TransductionStomatitisAnimalsCytokinesDisease Models, AnimalFemaleHead and Neck NeoplasmsHumansInflammationMiceCytokinesReceptors, Pattern Recognition

Identifiers

PMID33770116
PMCPMC7997003
OpenAlexW3136739351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.